Acetic Acid

Acetic Acid

SCHEMBL4412167

CC(=O)O.CCN[C@@H](CCCNC(=N)N)C(=O)O

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 7/20 0.40
C3AR1 Q16581 1/20 0.36
NOD1 Q9Y239 3/20 0.35
ITGB3 P05106 1/20 0.35
ITGA2B P08514 1/20 0.35
NPY4R P50391 3/20 0.33
NPY1R P25929 2/20 0.33
NPY2R P49146 2/20 0.33
NPY5R Q15761 2/20 0.33
TLR2 O60603 1/20 0.33
ALOX15 P16050 1/20 0.33
SIRT6 Q8N6T7 1/20 0.33
SIRT1 Q96EB6 1/20 0.33
GGT1 P19440 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1263209 0.97 FOLH1 (0.39) FOLH1C3AR1NOD1ITGB3ITGA2B
SCHEMBL61231 0.97 FOLH1 (0.39) FOLH1C3AR1NOD1ITGB3ITGA2B
SCHEMBL1419574 0.92 FOLH1 (0.44) FOLH1NOD1TLR2ALOX15SIRT6
SCHEMBL27675576 0.92 FOLH1 (0.44) FOLH1NOD1TLR2ALOX15SIRT6
SCHEMBL11950325 0.88 NPY4R (0.36) FOLH1NPY4RNPY1RNPY2RNPY5R
SCHEMBL16383647 0.88 NPY4R (0.36) FOLH1NPY4RNPY1RNPY2RNPY5R
SCHEMBL350197 0.86 NOD1 (0.41) FOLH1C3AR1NOD1ITGB3ITGA2B
SCHEMBL350198 0.86 NOD1 (0.41) FOLH1C3AR1NOD1ITGB3ITGA2B
SCHEMBL5605498 0.86 FOLH1 (0.38) FOLH1C3AR1NOD1ITGB3ITGA2B
Dodecanoate SCHEMBL28478322 0.85 NOD1 (0.46) NOD1TLR2ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298747-A1 Methods and Compositions For Treatment of Nitric Oxide-Induced Clinical Conditions BIO HOLDING, INC. (US) 2009-12-03 US claimed
US-6864086-B2 Nitric oxide-scavenging system for culturing oocytes, embryos, or other cells BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2005-03-08 US claimed
US-20040220242-A1 Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions BIO HOLDING, INC. 2004-11-04 US claimed
US-20040220113-A1 Inhibitors of serine protease activity methods and compositions for treatment of nitric oxide-induced clinical conditions BIO HOLDING, INC. 2004-11-04 US claimed
WO-2000051623-A2 INHIBITORS OF SERINE PROTEASE ACTIVITY, METHODS AND COMPOSITIONS FOR TREATMENT OF NITRIC OXIDE-INDUCED CLINICAL CONDITIONS THE TRUSTEES OF UNIVERSITY TECHNOLOGY CORPORATION (US) 2000-09-08 WO claimed
US-20090298747-A1 Methods and Compositions For Treatment of Nitric Oxide-Induced Clinical Conditions BIO HOLDING, INC. (US) 2009-12-03 US disclosed
US-20070224671-A1 Inhibitors of serine protease activity methods and compositions for treatment of nitric oxide-induced clinical conditions BIO HOLDING, INC. 2007-09-27 US disclosed
US-6864086-B2 Nitric oxide-scavenging system for culturing oocytes, embryos, or other cells BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2005-03-08 US disclosed
US-20040220113-A1 Inhibitors of serine protease activity methods and compositions for treatment of nitric oxide-induced clinical conditions BIO HOLDING, INC. 2004-11-04 US disclosed
US-20040220242-A1 Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions BIO HOLDING, INC. 2004-11-04 US disclosed
US-20030068816-A1 Nitric oxide-scavenging system for culturing oocytes, embryos, or other cells HANSEL WILLIAM (US) 2003-04-10 US disclosed
US-6489308-B1 ONE AGENT EXHIBITING MAMMALIAN ALPHA 1-ANTITRYPSIN OR ALPHA 1-ANTITRYPSIN-LIKE ACTIVITY, AND A FREE RADICAL SCAVENGER SUCH AS 2,6,8-TRIHYDROXYPURINE, DIHYDRORHODAMINE, OR A COMBINATION THEREOF TRUSTEES OF UNIVERSITY OF TECHNOLOGY CORPORATION 2002-12-03 US disclosed
US-6426219-B2 CULTURE CONTAINS A NITRIC OXIDE INHIBITOR SUCH AS FREE HEMOGLOBIN BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE 2002-07-30 US disclosed
US-20010034060-A1 Nitric oxide-scavenging system for culturing oocytes, embryos, or other cells HANSEL WILLIAM (US) 2001-10-25 US disclosed
US-6255109-B1 CULTURING MAMMALIAN OOCYTES OR EMBRYOS IN A CO-CULTURE SYSTEM IN THE PRESENCE OF HEMOGLOBIN, A NITRIC OXIDE INHIBITOR; PROMOTING THE MAINTENANCE, GROWTH AND DEVELOPMENT OF CELLS AND ELIMINATES TOXIC EFFECTS OF NITRIC OXIDE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE 2001-07-03 US disclosed
WO-2000051623-A2 INHIBITORS OF SERINE PROTEASE ACTIVITY, METHODS AND COMPOSITIONS FOR TREATMENT OF NITRIC OXIDE-INDUCED CLINICAL CONDITIONS THE TRUSTEES OF UNIVERSITY TECHNOLOGY CORPORATION (US) 2000-09-08 WO disclosed